Femara (Fe-MAR-a, letrozole), a new hormonal therapy for advanced breast cancer

September 1997

Novartis will soon launch Femara (Fe-MAR-a, letrozole), a new hormonal therapy for advanced breast cancer.

It's for postmenopausal women whose cancer progresses despite treatment with an antiestrogen such as tamoxifen (Nolvadex).

Femara is an aromatase inhibitor. Blocking this enzyme inhibits the PRODUCTION of estrogen in peripheral tissues.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

How herbs interact with "regular" drugs
Pulmicort Turbuhaler, a new DRY POWDER inhaler for asthma
Osteoarthritis Two unique new treatments for osteoarthritis of the knee
Pediatrics What do you tell a parent who asks if an antibiotic tastes good?
Pediatrics Ritalin (methylphenidate) to children with epilepsy
Pediatrics Efalex Focus, a new dietary supplement for children
Dermatology Now warning patients NOT to use Skin-Cap
Diabetes Rezulin (troglitazone) is now approved for INITIAL therapy of type 2 diabetes
Diabetes Medicare will cover more diabetes supplies and services
Diabetes Allow pharmacists to join together in networks to provide pharmaceutical care SERVICES
Breast Cancer Femara (Fe-MAR-a, letrozole), a new hormonal therapy for advanced breast cancer
Breast Cancer New screening device to help detect breast cancer
Cardiology Nicotine replacement therapy even for patients with coronary artery disease
Actis, a new Rx device for impotence
OTC product called Rejoyn
Ginkgo to try to improve sexual dysfunction caused by antidepressants
Interactions Drug interaction alerts are posing problems
Neurology & Pain Duract (bromfenac) for pain